New insights into APOE4's role in Alzheimer's disease reveal reversible vascular damage and protein accumulation mechanisms

How APOE4 Damages Brain Blood Vessels

Researchers at Mount Sinai have identified how APOE4, the strongest genetic risk factor for Alzheimer's disease, contributes to brain damage through multiple pathways. In a study published in Cell on September 24, scientists constructed a detailed single-cell transcriptomic atlas of human brain blood vessels to map how APOE4 affects the vascular system. The research revealed that APOE4 transforms pericytes—cells that stabilize small blood vessels and maintain the blood-brain barrier—into myofibroblast-like cells that produce scar tissue. This transformation triggers vascular fibrosis and promotes amyloid accumulation around blood vessels, potentially disrupting blood flow and creating environments conducive to neurodegeneration. Critically, the researchers discovered this process may be reversible: blocking TGF-β signaling, a key cell communication pathway involved in tissue remodeling, restored pericyte coverage while reducing both fibrosis and amyloid buildup. These results were confirmed in aged mice carrying APOE4, demonstrating that vascular degeneration is not simply a late consequence of Alzheimer's but rather an active, biologically driven process that could be therapeutically targeted.

Alzheimer's disease affects more than 7 million older adults in the United States and gradually damages memory, thinking, and behavior. While researchers have long observed that brain blood vessels deteriorate as the disease progresses—particularly in APOE4 carriers—the mechanisms underlying this vascular damage and its direct contribution to disease development remained unclear. By treating vascular degeneration as a consequence rather than a driver of neurodegeneration, previous approaches may have overlooked critical intervention points. The Mount Sinai findings reframe vascular damage as a biologically active process worthy of direct therapeutic attention, suggesting that preserving blood vessel function could limit amyloid accumulation and provide protective benefits for genetically at-risk populations.

Abnormal Protein Buildup and Cholesterol Metabolism

A companion study published in Cell Stem Cell explored another mechanism by which APOE4 contributes to neurodegeneration: disruption of the brain's protein cleanup systems. Using miBrains—three-dimensional human brain tissue engineered from induced pluripotent stem cells—researchers investigated why abnormal proteins accumulate in conditions like Alzheimer's and Parkinson's disease. While abnormal protein deposits define these neurodegenerative conditions, the cellular mechanisms driving their formation have remained poorly understood, partly because studying these processes in living human brains is technically difficult.

The experiments revealed that APOE4 causes cholesterol to accumulate inside astrocytes, support cells essential for maintaining brain health. This excess cholesterol interferes with the lysosomal waste-disposal system within astrocytes, rendering these cells less effective at breaking down alpha-synuclein, an abnormal protein most strongly associated with Parkinson's disease and Lewy body dementia. Rather than being cleared, accumulated alpha-synuclein spreads to neurons where it forms toxic deposits. These findings identify cholesterol metabolism within astrocytes and lysosomal function as potential therapeutic targets for both Alzheimer's and Parkinson's disease, suggesting that modulating lipid metabolism could enhance cellular waste removal and reduce harmful protein buildup.

miBrains: A Novel Platform for Disease Modeling and Personalized Medicine

Central to both studies is miBrains, an innovative human brain tissue platform derived from stem cells. These three-dimensional constructs reproduce important features of human brain tissue, including its network of blood vessels and all major cell types present in the brain—neurons, glial support cells, myelin-producing cells, and vascular cells. The miBrain system enabled researchers to recreate events that occur before severe vascular abnormalities become visible in postmortem tissue, allowing identification of underlying mechanisms and rapid testing of potential treatments.

A significant technical advance is the ability to cryopreserve miBrains with predefined cellular compositions and disease-related factors, improving reproducibility and scalability of disease modeling while supporting more efficient drug development and validation. Most ambitiously, Mount Sinai researchers are developing patient-derived miBrains that could eventually enable personalized investigation of how neurodegenerative disease develops across individuals and how specific patients might respond to particular treatments. This capability could help bridge the gap between laboratory discoveries and clinical treatments, allowing potential therapies to be tested earlier and more efficiently than traditional development pathways. By combining miBrain observations with preclinical models, postmortem human brain tissue analysis, and transcriptomic data, the research team strengthened findings across multiple complementary systems, demonstrating the power of integrated experimental approaches in understanding complex brain diseases.